My Treatment Approach Beyond the First-Line: Expert Insights on Evidence-Driven TKI Selection and Sequencing in Advanced GIST - Episode 8
Managing Adverse Events With Different TKIs
Experts discuss how they approach managing adverse events with tyrosine kinase inhibitors (TKIs) like ripretinib, sunitinib, and regorafenib, highlighting notable differences in their safety profiles and how these differences influence treatment decisions.
Video Player is loading.
Video content above is prompted by the following:
- Beyond efficacy considerations, how do you approach managing adverse events with TKIs like ripretinib, sunitinib, and regorafenib? Are there notable differences in their safety profiles that influence your treatment decisions?
Related Content:
